HRA008226
Title:
NOTCH1 mutation predicts better clinical survival benefit of tislelizumab in second-line esophageal squamous cell carcinoma: a RATIONALE-302 study biomarker analysis
Release date:
2024-08-09
Description:
Retrospectively collected adjacent and tumor samples from 30 esophageal cancer patients were subjected to whole-exome sequencing. Additionally, multiplex immunofluorescence staining was performed on patient tissue sections. The study found that, compared to patients with wild-type NOTCH1, those with NOTCH1-mutant esophageal cancer exhibited significantly lower proportions of B cells and neutrophils in their tumor tissues.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cohort Study
Disease name:
esophageal cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Esophageal Cancer Management
Contact person:
Lu Zhihao
Email:
zhihaolupku@bjmu.edu.cn
Description:
Esophageal Cancer Management
Individuals & samples
Submitter:   Lu Zhihao / zhihaolupku@bjmu.edu.cn
Organization:   Peking University Cancer Hospital
Submission date:   2024-08-07
Requests:   -